Feature

GRIN targeting rare pediatric neurological disorders with precision therapies

Closely-held GRIN Therapeutics, a Neurvati Neuroscience company, is advancing promising research and development of precision therapeutics for neurodevelopmental disorders, predominately affecting children from infancy...

December 17, 2024

Feature

Perimeter’s positive topline results signal potential for wide-spread user adoption of next-gen, ultra-high-res, AI-driven imaging tool during breast cancer surgeries

Perimeter Medical Imaging AI (TSX-V:PINK; OTC:PYNKF) is poised to transform cancer surgery, as positive topline results from a pivotal study designed to support the company’s planned FDA premarket approval (PMA)...

December 3, 2024

Feature

Clearmind spearheading novel, life-changing psychedelic solutions for binge behaviors and mental health

Clearmind Medicine (NASDAQ:CMND; FSE:CWY0) is discovering and developing safe, novel psychedelic-derived therapeutic candidates with its new psychoactive molecule, 5-Methoxy-2-aminoindane (MEAI), to address widespread...

November 26, 2024

Feature

Spectral combining diagnostics with targeted therapy in novel approach to septic shock

Spectral Medical (TSX: EDT) is seeking to improve outcomes for millions of patients with life-threatening endotoxic septic shock (ESS), by combining its targeted diagnostic, Endotoxin Activity Assay (EAA), with its...

November 12, 2024